Ultra‑fast (FLASH) proton and carbon radiation to spare healthy tissue
Translational Studies in FLASH Particle Radiotherapy
This project tests whether ultra‑high‑dose‑rate proton and carbon particle radiation can better protect healthy tissues while treating cancers like pancreatic cancer and sarcoma.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11298922 on NIH RePORTER |
What this research studies
From a patient perspective, researchers are comparing ultra‑fast FLASH particle beams to standard particle radiation to see if FLASH reduces damage to normal organs without weakening tumor control. The team will run lab and animal experiments, including genetic mouse models that look at intestinal stem cell survival, and study inflammation, fibrosis, lymphedema, bone changes, and risk of treatment‑related cancers. They will also run a phase 1/2 veterinary trial in dogs with cancer as a translational step toward human use. The work combines dosimetry, biological studies, and genetic analyses to identify how FLASH might protect normal tissue.
Who could benefit from this research
Good fit: People with cancers commonly treated with particle radiotherapy—especially pancreatic cancer or soft‑tissue sarcomas—or those at high risk for gastrointestinal or soft‑tissue radiation injury could be candidates for future trials.
Not a fit: Patients whose tumors are not treated with particle beams, who cannot travel to specialized particle therapy centers, or whose care depends primarily on systemic therapies may not benefit directly from this project.
Why it matters
Potential benefit: If successful, this approach could lower radiation side effects and long‑term complications while keeping cancer control strong.
How similar studies have performed: Preclinical FLASH studies have shown promising normal‑tissue sparing and a few early clinical reports exist, but robust clinical evidence—especially for particle FLASH—is still limited.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Koumenis, Constantinos — University of Pennsylvania
- Study coordinator: Koumenis, Constantinos
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.